A phase Ib/IIa clinical trial to combine the CSF1 receptor inhibitor pexidartinib with the androgen receptor antagonist enzalutamide in metastatic castration resistant prostate cancer

Trial Profile

A phase Ib/IIa clinical trial to combine the CSF1 receptor inhibitor pexidartinib with the androgen receptor antagonist enzalutamide in metastatic castration resistant prostate cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 May 2017

At a glance

  • Drugs Pexidartinib (Primary) ; Enzalutamide
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms POLERISE
  • Most Recent Events

    • 10 Apr 2017 Status changed from not yet recruiting to recruiting.
    • 30 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top